Patents by Inventor Stefan Knackmuss

Stefan Knackmuss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CD16 binding molecules
    Patent number: 9035026
    Abstract: The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc?RIIIA), and in particular binding molecules that specifically bind the A form Fc?RIII but do not bind to the B form of Fc?RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: May 19, 2015
    Assignee: Affimed GMBH
    Inventors: Karin Hoffmann, Sergey Kipriyanov, Stefan Knackmuss, Fabrice Le Gall, Melvyn Little, Uwe Reusch
  • COMPOUNDS FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE
    Publication number: 20140220041
    Abstract: The invention relates to a method of modulating concentration of Alzheimer's Disease (AD) relevant proteins amyloid precursor protein (APP), beta (?) and gamma (?) secretases and amyloid beta peptide (A?), and also relates to a method of reducing A? shedding. Furthermore, this invention extends to a compound for use in the treatment of AD, and also to a method of treating AD.
    Type: Application
    Filed: September 19, 2012
    Publication date: August 7, 2014
    Applicant: University of the Witwatersrand, Johannesburg
    Inventors: Stefan Franz Thomas Weiss, Katarina Jovanovic, Danielle Gonsavles, Bianca Da Costa Dias, Stefan Knackmuss, Uwe Reusch, Melvyn Little, Marc Saul Weinberg
  • Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa
    Patent number: 8455627
    Abstract: The present invention is directed to an antibody or derivative thereof of human origin for inhibiting platelet aggregation, characterized in that it is effective by substantially exclusive binding to the activated state of platelet integrin receptor GPIIb/IIIa.
    Type: Grant
    Filed: September 7, 2010
    Date of Patent: June 4, 2013
    Assignee: Affimed Therapeutics, AG
    Inventors: Claudia Linhard, Stefan Knackmuss, Melvyn Little, Karlheinz Peter, Peter Roettgen, Meike Schwarz
  • ANTIBODY OF HUMAN ORIGIN FOR INHIBITING THROMBOCYTES AGGREGATION
    Publication number: 20110165175
    Abstract: The present invention is directed to an antibody or derivative thereof of human origin for inhibiting platelet aggregation, characterized in that it is effective by substantially exclusive binding to the activated state of platelet integrin receptor GPIIb/IIIa.
    Type: Application
    Filed: September 7, 2010
    Publication date: July 7, 2011
    Inventors: Claudia Linhard, Stefan Knackmuss, Melvyn Little, Karlheinz Peter, Peter Roettgen, Meike Schwarz
  • Use of an antibody against the laminin receptor or laminin receptor precursor for the treatment or diagnosis of several cancer types
    Patent number: 7901677
    Abstract: Described is the use of a recombinant antibody comprising a binding site specific for an epitope of the laminin receptor or laminin receptor precursor for the treatment or diagnosis of various cancers, particularly B-CLL. Preferably, this antibody additionally comprises a binding site for at least one particular cell surface antigen.
    Type: Grant
    Filed: April 5, 2006
    Date of Patent: March 8, 2011
    Assignee: Affimed Therapeutics AG
    Inventors: Melvyn Little, Stefan Knackmuss, Uwe Reusch, Sergey Kipriyanov, Fabrice Le Gall, Vera Mick, Karin Hoffmann, Peter Röttgen
  • Antibody of human origin specifically binding to activated state of platelet integrin receptor GPIIb/IIIa
    Patent number: 7812136
    Abstract: The present invention is directed to an antibody or derivative thereof of human origin for inhibiting platelet aggregation, characterized in that it is effective by substantially exclusive binding to the activated state of platelet integrin receptor GPIIb/IIIa.
    Type: Grant
    Filed: October 4, 2002
    Date of Patent: October 12, 2010
    Assignee: Affimed Therapeutics, AG
    Inventors: Claudia Buettner, Stefan Knackmuss, Melvyn Little, Karlheinz Peter, Peter Roettgen, Meike Schwarz
  • Anti-cd16 binding molecules
    Publication number: 20090214574
    Abstract: The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc?RIIIA), and in particular binding molecules that specifically bind the A form Fc?RIII but do not bind to the B form of Fc?RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.
    Type: Application
    Filed: May 26, 2006
    Publication date: August 27, 2009
    Inventors: Karin Hoffmann, Sergey Kipriyanov, Stefan Knackmuss, Fabrice Le Gall, Melvyn Little, Uwe Reusch
  • Single-chain antibody acting against 37 kDa/67 kDa Iaminin receptor as tools for the diagnosis and therapy of prion diseases and cancer, production and use thereof
    Patent number: 7507797
    Abstract: Single-chain antibodies are described which specifically recognize both the 37 kDa precursor form of the laminin receptor (37 kDa LRP) and the 67 kDa high-affinity form of the laminin receptor (67 kDa LR), and pharmaceutical and diagnostic compositions which contain these single-chain antibodies.
    Type: Grant
    Filed: October 8, 2004
    Date of Patent: March 24, 2009
    Assignee: Affimed Therapeutics AG
    Inventors: Stefan Knackmuss, Clémence Rey, Peter Röttgen, Claudia Büttner, Uwe Reusch
  • Single-chain antibody acting against 37 kda/67 kda laminin receptor as tools for the diagnosis and therapy of prion diseases and cancer, production and use thereof
    Publication number: 20070041977
    Abstract: Single-chain antibodies are described which specifically recognize both the 37 kDa precursor form of the laminin receptor (37 kDa LRP) and the 67 kDa high-affinity form of the laminin receptor (67 kDa LR), and pharmaceutical and diagnostic compositions which contain these single-chain antibodies.
    Type: Application
    Filed: October 8, 2004
    Publication date: February 22, 2007
    Inventors: Stefan Knackmuss, Clemence Rey, Peter Rottgen, Claudia Buttner, Uwe Reusch